© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
April 14th 2021
Shannon N. Westin, MD, MPH, FACOG, discusses the rationale for the use of combination immunotherapy for advanced and recurrent endometrial cancer.
May 4th 2021
Vicky Makker, MD, reviews the trial design and efficacy data for the open-label, randomized phase 3 KEYNOTE-775/Study 309 in patients with advanced endometrial cancer.
Vicky Makker, MD, reviews the safety profile of lenvatinib-pembrolizumab in advanced endometrial cancer from the phase 3 KEYNOTE-775/Study 309 trial and the management of common adverse events.
May 12th 2021
Vicky Makker, MD, and Shannon N. Westin, MD, MPH, FACOG, discuss their experiences using lenvatinib-pembrolizumab therapy for advanced endometrial cancer.
Experts in gynecologic oncology share insights on patient selection for lenvatinib-pembrolizumab in advanced endometrial cancer and discuss therapeutic sequencing through multiple lines of therapy.